Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
暂无分享,去创建一个
[1] A. Makris,et al. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer , 2006, Cancer Chemotherapy and Pharmacology.
[2] 澤木 正孝. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer : a single-center study , 2005 .
[3] J B Vermorken,et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] D. Lake,et al. Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer , 2004, Clinical Cancer Research.
[5] J. Hainsworth,et al. First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial , 2004 .
[6] C. Veyret,et al. Neoadjuvant weekly paclitaxel, and epirubicin (PE) in patients with inflammatory and T4 breast cancer (IBC-T4BC): Result of a VAR Cancer Society tria , 2004 .
[7] P. Saintigny,et al. Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Thomas,et al. Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III tria. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Steder,et al. Weekly vinorelbine (VIN) vs weekly docetaxel (DOC) for metastatic breast cancer failing anthracyclines. Planned interim analysis of a randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Russo,et al. Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Thomas,et al. Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Thomas,et al. Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] N. Guler,et al. Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. , 2004, The Tohoku journal of experimental medicine.
[14] Hajime Tanaka,et al. [Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multi-center cooperative clinical trial]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.
[15] M. Gnant,et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study , 2004, Journal of Cancer Research and Clinical Oncology.
[16] D. Crivellari,et al. Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study , 2004, Tumori.
[17] Suzanne F. Jones,et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Paridaens,et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study , 2004, Anti-cancer drugs.
[19] Yu Shyr,et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Østenstad,et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer , 2004, Acta oncologica.
[21] K. Wernecke,et al. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. , 2004, Anticancer research.
[22] A. Negassa,et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. , 2004, Clinical breast cancer.
[23] C. Seynaeve,et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. , 2004, European journal of cancer.
[24] L. Crinò,et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer , 2004, British Journal of Cancer.
[25] E. Perez,et al. Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer* , 2002, Breast Cancer Research and Treatment.
[26] G. D'aiuto,et al. Cisplatin–epirubicin–paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology group (SICOG) phase II study , 2000, Breast Cancer Research and Treatment.
[27] G. D'aiuto,et al. Cisplatin–epirubicin–paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group , 1999, Breast Cancer Research and Treatment.
[28] G. D'aiuto,et al. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study , 1998, Breast Cancer Research and Treatment.
[29] J. Hainsworth,et al. First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Chahine,et al. Phase II study of sequential administration of vinorelbine -capecitabine combination followed by weekly docetaxel as first line chemotherapy for advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Toi,et al. Protracted administration of weekly docetaxel in metastatic breast cancer. , 2003, Oncology reports.
[32] Tsuyoshi Saito,et al. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). , 2003, Japanese journal of clinical oncology.
[33] M. Mesiti,et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? , 2003, Anticancer research.
[34] A. Glasmacher,et al. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial , 2003, Anti-cancer drugs.
[35] D. Neuberg,et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Antón,et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] M. Ramos,et al. Weekly Docetaxel as Second-Line Therapy for Patients with Advanced Breast Cancer Resistant to Previous Anthracycline Treatment , 2003, Journal of chemotherapy.
[38] J. Sgouros,et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. , 2003, Anticancer research.
[39] S. Ricci,et al. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. , 2002, Clinical breast cancer.
[40] M. Tonato,et al. Weekly Paclitaxel in Metastatic Breast Cancer Patients: A Phase II Study , 2002, Tumori.
[41] G. Sledge,et al. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] N. Robert,et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Gnant,et al. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer , 2002, Cancer Chemotherapy and Pharmacology.
[44] Terry L. Smith,et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] T. Aihara,et al. Phase II study of weekly docetaxel in patients with metastatic breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] M. Campiglio,et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] A. Riccardi,et al. Weekly Administration of Gemcitabine Plus Docetaxel in Patients with Advanced Breast Cancer: A Phase 1 Study , 2002, Oncology.
[48] A. Seidman,et al. Critical Review of Current Treatment Strategies for Advanced Hormone Insensitive Breast Cancer , 2002, Cancer investigation.
[49] E. Perez,et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] A. Adamou,et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] J. Hainsworth,et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] K S Panageas,et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] W. Scheithauer,et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Y. Tanigawara,et al. Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer , 2001, International Journal of Clinical Oncology.
[55] P. Mallmann,et al. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer , 2000, Anti-cancer drugs.
[56] M. Ducreux,et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.
[57] H. Muss,et al. New strategies for managing metastatic breast cancer. , 2000, Oncology.
[58] J. Crown,et al. The taxanes: an update , 2000, The Lancet.
[59] J. Manola,et al. Docetaxel administered on a weekly basis for metastatic breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] R. Thomas,et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] J. Klijn,et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] N. Pavlidis,et al. Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study , 2000, Cancer investigation.
[63] S. Agelaki,et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors , 2000, Cancer Chemotherapy and Pharmacology.
[64] K. Friedrichs,et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] N. Pavlidis,et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] S. Agelaki,et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] C. Hudis,et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] J. Schellens,et al. Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. , 1998, Anti-cancer drugs.
[69] J. Hainsworth,et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] K. Ridwelski,et al. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study. , 1997, Seminars in oncology.
[71] H. Safran,et al. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. , 1997, Seminars in oncology.
[72] H. Lück,et al. Phase I study of weekly docetaxel (Taxotere®) in heavily pretreated breast cancer patients , 1997 .
[73] A. Seidman,et al. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. , 1997, Seminars in oncology.
[74] M. Aapro,et al. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. , 1997, Oncology.
[75] K. Gelmon,et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] P M Ravdin,et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] V. Valero,et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] C. Hudis,et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] C. Hudis,et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] M. Piccart,et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] G. Hortobagyi,et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.
[82] I. Ringel,et al. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.